Earnings call
Acutaas Chemicals Q3 FY25 earnings call: Several additional projects in Ami Organics Limited's CDMO pipeline have progressed to final stages, and most are expected to begin commercialization by FY '26
By DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person.
Transcript filed .
Several additional projects in Ami Organics Limited's CDMO pipeline have progressed to final stages, and most are expected to begin commercialization by FY '26. Ami Organics Limited's capital expenditure for the first 9 months of FY '25 was INR 118 crores, primarily allocated to the Ankleshwar site, solar and electrolyte additive projects. Ami Organics Limited's revenue for the first 9 months of FY '25 was INR 698 crores, nearly the same as its revenue for the entire previous financial year. Ami Organics Limited expects demand for apixaban API and API manufacturing to increase following its expiry in '26; demand has already started, with a small quantity ramp-up in Q3, a little higher in Q4, and a moderate level expected by FY '26 after minimal activity in the last couple of financial years. Ami Organics had more than 570 molecules through last year's invoice and expects to add another 40 to 50 molecules this year.
The numbers management gave
Results
- Ami Organics Limited's revenue for the first 9 months of FY '25 was INR 698 crores, nearly the same as its revenue for the entire previous financial year.
Show source
Moving on to the business performance: Page 3 of 21 Ami Organics Limited Jan 29, 2025 I am pleased to share that we have already reached nearly the same revenue as the entire previous financial year within the first 9 months of FY '25, totalling INR 698 crores.
- Ami Organics Limited's revenue from operations in Q3 FY '25 was INR 275 crores, up 65.2% year-on-year and 11.5% sequentially, driven by a ramp-up in CDMO and steady growth in Advanced Pharmaceutical Intermediate.
Show source
Looking at the quarterly numbers, we have continued to deliver robust growth with revenue from operations increasing by 65.2% year-on-year, and 11.5% sequentially to INR 275 crores.
- Ami Organics Limited's Specialty Chemical segment reported revenue of INR 36 crores in Q3 FY '25, a slight decline compared with the same quarter last year.
Show source
Now Specialty Chemical business: The segment reported revenue of INR 36 crores; a slight decline compared to the same quarter last year.
- Ami Organics Limited's Specialty Chemical revenue declined around 11% sequentially in Q3 FY '25, primarily due to lower volume in its commodity Chemical business.
Show source
Sequentially, revenue dropped by around 11%, primarily due to lower volume in our commodity Chemical business.
- Ami Organics Limited's BFC business was flat year-on-year and showed sequential growth in Q3 FY '25.
Show source
Page 4 of 21 Ami Organics Limited Jan 29, 2025 Within Specialty Chemicals, the BFC business remained flat year-on-year, but showed steady sequential growth.
- Ami Organics Limited's gross profit in Q3 FY '25 was INR 127.2 crores, an increase of 78% compared with the same period last year.
Show source
Gross profit for the quarter was INR 127.2 crores, reflecting 78% increase compared to the same period last year.
Show 13 more statements
Results
- Ami Organics Limited's gross margin in Q3 FY '25 expanded by 333 basis points year-on-year and 281 basis points sequentially to 46.2%, driven by better product mix.
Show source
The gross margin expanded by 333 basis points Y-o-Y, and 281 basis points sequentially to 46.2%.
- Ami Organics Limited's EBITDA in Q3 FY '25 was INR 68.7 crores, more than 2.5x the amount in the same period last year.
Show source
EBITDA for the quarter was INR 68.7 crores, which was more than 2.5x when compared to the same period last year.
- Ami Organics Limited's EBITDA margin in Q3 FY '25 was 25%, up 904 basis points year-on-year and 198 basis points quarter-on-quarter, driven by gross margin expansion and operating leverage.
Show source
EBITDA margin were at 25%, up 904 basis points Y-o-Y and 198 basis points Q-o-Q basis.
- Ami Organics Limited's PAT in Q3 FY '25 was INR 45.4 crores, more than 2.5x its PAT of INR 17.8 crores in Q3 FY '24.
Show source
PAT for the quarter was INR 45.4 crores, which grew more than 2.5x compared to the PAT of INR 17.8 crores in Q3 FY '24.
- Ami Organics Limited's PAT margin in Q3 FY '25 was 16.5%, up 582 basis points year-on-year and 130 basis points quarter-on-quarter.
Show source
PAT margin for the quarter was 16.5%, which shows expansion of 582 basis points Y-o-Y and 130 basis points on Q-o-Q basis.
- Ami Organics Limited's revenue from operations for the 9 months FY '25 was INR 698 crores, up 41.8% year-over-year and nearly equal to its full-year revenue for FY '24.
Show source
Moving on to the performance for the 9 months: Page 5 of 21 Ami Organics Limited Jan 29, 2025 Revenue from operations for the 9 months '25 reached INR 698 crores, representing a growth of 41.8% year-over-year.
- Ami Organics Limited's EBITDA for the 9 months FY '25 was INR 146.6 crores, up 41.8% year-on-year.
Show source
EBITDA for the 9 months FY '25 was INR 146.6 crores, up 41.8% Y-o-Y. PAT for 9 months FY '25 was at INR 97.7 crores, up 78.3% Y-o-Y when compared to the adjusted PAT for the same period last year.
- Ami Organics Limited's PAT for the 9 months FY '25 was INR 97.7 crores, up 78.3% year-on-year compared with adjusted PAT for the same period last year.
Show source
EBITDA for the 9 months FY '25 was INR 146.6 crores, up 41.8% Y-o-Y. PAT for 9 months FY '25 was at INR 97.7 crores, up 78.3% Y-o-Y when compared to the adjusted PAT for the same period last year.
- Ami Organics Limited's working capital was 95 days during 9 months FY '25, compared with 108 days as on H1 FY '25, driven by improved debtor days and stable inventory.
Show source
I am happy to share that even with strong growth, we were able to control our working capital, which was 95 days during 9 months FY '25 as against 108 days as on H1 FY '25.
- Ami Organics Limited generated INR 119 crores of cash flow from operations during 9 months FY '25, equal to 81% of EBITDA for the period, as a result of better working capital management.
Show source
Better working capital management led to strong generation of cash flow from operations of INR 119 crores, which was 81% of the EBITDA for the 9 months FY '25.
- Ami Organics' CDMO business generated INR 90 crores last year and had already crossed more than double that business this year.
Show source
This year, we have already crossed more than double of that last year's business.
- Ami Organics' blended margin was 21% in 9 months FY '24, and it expects the margin to improve in Q4.
Show source
Abhishek Patel: So, as on date for 9 months, our blended margin is 21% in 9 months FY '24.
Money and capital
- Ami Organics Limited's net cash and cash equivalents were INR 306 crores.
Show source
Moving on to the balance sheet items: Net cash and cash equivalents were at INR 306 crores.
What it expects ahead
What management expects
- Several additional projects in Ami Organics Limited's CDMO pipeline have progressed to final stages, and most are expected to begin commercialization by FY '26.
Show source
Discussions with innovators and partners are progressing well, and most of these projects are expected to begin commercialization by FY '26.
- Ami Organics Limited anticipates its overall CDMO business to reach approximately INR 1,000 crores by FY '28, compared with INR 80 - 90 crores in the last financial year.
Show source
Consequently, we anticipate our overall CDMO business to reach approximately INR 1,000 crores by FY '28, compared to INR 80 - 90 crores in the last financial year.
- Ami Organics Limited revised its FY '25 growth guidance upward from 30% to 35%, and expects to beat its previous growth estimate based on better visibility of Q4.
Show source
And therefore, I would like to revise growth guidance upward from 30% to 35% for FY '25.
- Ami Organics Limited expects consistent growth in BFC revenue from Q3 FY '25 onward, as it believes Q2 was the bottom for BFC revenue.
Show source
We believe Q2 was the bottom for BFC revenue, and we expect consistent growth from here onwards.
- Ami Organics Limited expects more than 35% growth for FY '25 with improved EBITDA margins.
Show source
Overall, as Naresh sir has mentioned, we are well on the track to deliver more than 35% of growth for the year with improved EBITDA margins.
- Ami Organics Limited expects sequential improvement in revenue and margins in the next financial year and expects its full-year EBITDA margin to exceed its highest peak EBITDA margin of more than 23.5%.
Show source
But on a blended side, we can expect that we will cross the EBITDA margin for the full year of the highest peak EBITDA margin of more than 23.5%, which we recorded our highest margin.
Show 11 more statements
What management expects
- Ami Organics said its EBITDA margin can reach 27% to 30% as the CDMO business ramps up and commercialization of two other blocks improves operational efficiency, while noting it guides conservatively because this is an intermediate business, not an API business.
Show source
It can reach to, let's say, 27% to 30% also.
- Ami Organics said the 4,000 metric ton plant, inclusive of all additives, will provide guidance about revenue and margin from the beginning; margins for Electrolyte Additives are expected to be better than Specialty but lower than Pharma.
Show source
So, this is the same thing which is right now is applicable for us in terms of Electrolyte Additives as well.
- Ami Organics said semiconductor margins are much higher than Pharma and CDMO and may vary from 40% to 65%, depending on the product, scale and customer.
Show source
Nareshkumar Patel: No. Semicon is a very different ball of game, where we are the only company in India, who are right now have a good situation and position ourselves in this basic chemical supply, where the margins are much higher than the Pharma as well as CDMO, which it may vary from 40% to 65%, depends on which product at what scale and this all depends on customer to customer as well.
- Ami Organics targets 3x asset turns on investments.
Show source
Nareshkumar Patel: Normally, we target any asset turns which we invest would be 3x.
- Ami Organics said overall growth for the year would be 35%.
Show source
Nareshkumar Patel: We already announced that this quarter growth, the overall year will be 35%.
- Ami Organics anticipated full-year growth of more than 15% excluding BFC.
Show source
Abhishek Patel: Ex of BFC, the growth anticipated for full year is more than 15%.
- Ami Organics said it wants to double in 3 years' time and committed to growth guidance of 25% to more than 25%.
Show source
And so that's a 25% to more than 25% growth guidance we are committing.
- Ami Organics expects its full-year blended margin in FY '26 to reach its highest margin ever reported, with sequential improvement from Q1 to Q4.
Show source
And for FY '26 for full year, we are expecting this margin on a blended basis to reach at a peak or highest margin ever reported by Ami Organics.
- Ami Organics Limited expects quarter-on-quarter improvement in gross margin and EBITDA going forward in the next financial year.
Show source
Abhishek Patel : So, on the margin side, as you know that we have improved GM by 281 basis points in this financial and EBITDA of 5%, and we expect quarter-on-quarter improvement going forward in next financial year also.
- Ami Organics is maintaining the status quo on the Korean JV Solution business because it does not want to rush into a market that is yet to be fully developed or allocate or lock up capital; it will take a call at a relevant level.
Show source
But for Solution business, which is the Korean JV, which we announced earlier, that status quo, we are maintaining, because we don't want to rush into the market, which is yet to get fully developed and we don't want to allocate capital or struck our capital.
- Ami Organics Limited expects exponential growth from its New Chemical Entities business and CDMO and CMO business. Replaced by a later filing.
Show source
Regarding to the growth, which is exponential growth, which is expected by everyone, which is coming from our New Chemical Entities business as well as CDMO and CMO business.
What it is building and selling
Projects and capacity
- Ami Organics Limited's capital expenditure for the first 9 months of FY '25 was INR 118 crores, primarily allocated to the Ankleshwar site, solar and electrolyte additive projects.
Show source
Capital expenditure side: CAPEX for the first 9 months FY '25 stood at INR 118 crores, primarily allocated to Ankleshwar site as well as solar and electrolyte additive projects.
- Ami Organics Limited's electrolyte additive capital expenditure is ongoing and expected to be completed by H1 FY '26, securing revenue requirements for the next 3 years.
Show source
Coming to electrolyte additive CAPEX: The CAPEX is well on track and is expected to be completed by H1 FY '26.
- Ami Organics Limited's Unit-1 Sachin capacity is more than 70% utilized; Unit-2 Block 3, which is already capitalized, has reached 50% capacity utilization; and Unit-3 capacity utilization is 50%.
Show source
Abhishek Patel: From a capacity front, let me update that at Unit-1 Sachin, capacity is more than 70% utilized.
- Ami Organics Limited has available Pharma Intermediate capacity at Unit-2; Block 2 is inaugurated and Block 1 is expected to be commercialized by the end of this March quarter, supporting capacity requirements for the next 2 to 3 years.
Show source
So, it will cater largely our capacity requirement for next 2 to 3 years requirement.
- Ami Organics Limited's Spec-Chem capacity is at 50% utilization and is expected to cater to its capacity requirements for the next 3-year time.
Show source
So, that will also cater our capacity requirement for next 3-year time.
- Ami Organics Limited expects to acquire additional land 1.5, 2 years in advance as required for the next level of revenue growth; it has 8,000 square meter of land available at Sachin GIDC for additional requirements and may acquire more land for high capital expenditure in future.
Show source
Even today also, we have one 8,000 square meter land available at Sachin GIDC, which can be used for some additional requirement.
Show 6 more statements
Projects and capacity
- Ami Organics is undertaking CAPEX of INR 170 crores for its Electrolyte Additive business and said it has signed some supply contracts and has long-term visibility for the business.
Show source
Abhishek Patel: For CAPEX of INR 170 crores, that is for the purpose of Electrolyte Additive business, which is going on.
Demand and pricing
- Ami Organics Limited expects demand for apixaban API and API manufacturing to increase following its expiry in '26; demand has already started, with a small quantity ramp-up in Q3, a little higher in Q4, and a moderate level expected by FY '26 after minimal activity in the last couple of financial years.
Show source
And by FY '26, we are expecting to go at a very moderate level against the very minimized in last couple of financial years.
- Rivaroxaban expires in FY '26, '27; Ami Organics Limited expects a ramp-up by the end of this year and is already selling some quantities to partners in Europe and India.
Show source
So, it will be ramp up by end of this year.
Segments
- Ami Organics had more than 570 molecules through last year's invoice and expects to add another 40 to 50 molecules this year.
Show source
We have more than 570 molecules till last year invoice.
- Ami Organics was supplying around 60 to 80 molecules in clinical trials at Phase I or Phase II.
Show source
Out of that, in a clinical trial, somewhere around 60 to 80 molecules are right now either in Phase-II or Phase-I kind of things, which we are supplying to them.
- Ami Organics said it has no ARV and that Dolutegravir contributes almost 1% of total revenue.
Show source
Only Dolutegravir is there, but that is almost contributing 1% of the total revenue.
Risks, rules and outside factors
Outside factors
- Ami Organics Limited is observing near-term delays in commissioning new battery capacities and is focusing capital expenditure in the battery chemical segment on additives with long-term contracts in place.
Show source
We are adopting a cautious approach in the segment and focusing on capital expenditure for additives where we already have long-term contract in place.
- Ami Organics Limited's commodity chemicals pricing remained under pressure due to oversupply, unchanged from the previous quarter.
Show source
Commodity chemicals : Situation remains unchanged from the previous quarter with pricing under pressure due to oversupply.
What the company said on its earnings call, taken from its own transcript. Not advice.
Questions and answers
Question
Bharat Shah: Yes. Hi, Naresh Bhai, good morning. After all the efforts, finally, things seem to be settling in a right direction. I just wanted to understand, we have good visibility as far as our Pharma Intermediate and CDMO business is concerned for the next 2 years. But what are the steps we are taking to build growth engine intake after 2027? Next 2 years, as I understand the business, I think business is reasonably secured and clear. But after 2027, what are the initiatives which we’re building today in order to drive the growth engine ahead thereafter?
Answer, nareshkumar patel
Nareshkumar Patel: Good morning, Bharat Bhai. Thank you very much for asking this question. As you know that our business model is divided into the originator business, our own generic business as well as first-to-file business. So, we have business security till 2040. We had already done developing molecules for generic application up to 2040, which will cater our steady growth up to 2040 with the customer also secure. Page 6 of 21 Ami Organics Limited Jan 29, 2025 So, in that sense, we are not worried about the business. Regarding to the growth, which is exponential growth, which is expected by everyone, which is coming from our New Chemical Entities business as well as CDMO and CMO business.
Answer, nareshkumar patel
In Pharma, which is going very well, we have lot of CMO and CDMO in pipelines. One is very major. That's why it is highlighted very well, but there are some others which are also moderately good in quantity and quality in a revenue point of view. And we already said that in FY '26, some of them are coming out. Similarly, there are several which is coming in FY '27, '28, '29. So, we have a good visibility in terms of CMO, CDMO, because there are some molecules which are in Phase-III, some are in later stage of clinical approval also. So, that will bring our future growth into the business as well.
Answer, nareshkumar patel
And that is the reason why we had built out this new facility, considering this modern requirement and latest policy requirement by the FDA as well.
Question
Bharat Shah: So, apart from the generics where we have long-term visibility, are there further engines being built today for maintaining or accelerating growth beyond 2027?
Answer, nareshkumar patel
Nareshkumar Patel: Yes, sir. Baba Fine Chem is one of the master investments, I can say because that has a huge potential to grow in semiconductor sector. We are already producing photoresist chemical, but we have several another backend packaging side, also some chemicals, which already developed and now these monomers and chemicals we are sending in Japan and Korea, which will be mature in the next couple of years. So, adding a new additional growth driver for our future - the Electrolyte Additives, we have only 2 in the past, but now we have more than 12 Electrolyte Additives now. And these all will be used by all the battery cell manufacturers. And we have already started qualification staging with existing customer as well as the new customer. And beauty is that we have right from beginning, we are in line with the Chinese price.
Answer, nareshkumar patel
So, whether IRA will be there or not there, it is not impacting us, because Chinese price is in line with us. It will be, in fact, beneficial for us if the IRA is not there, then we can have leverage of raw material sourcing from other cheaper nations, and that will also help us to have an addition in the margin as well. So, this is a good move for us in terms of positioning ourselves in electrolyte as well.
Question
Bharat Shah: And on Specialty Chemicals, any insight you want to share?
Answer, nareshkumar patel
Nareshkumar Patel: Specialty Chemicals segment is a highly commoditized segment, which is we acquired from Gujarat Organics. We've done a lot of development in that site. We sustain ourselves. With this highly price pressure, raw material drop-down, topline eroded by 30%, even though we are sustaining the market share so far. So, that is the reason till now in the last 3 years, we had not declined our revenue in Specialty Chemicals, with maintaining the EBITDA at a double-digit level. So, that is a good achievement for us. Page 7 of 21 Ami Organics Limited Jan 29, 2025 Now we had also done some good qualification in regulated market for specialty chemical as well, which is under validation right now.
Answer, nareshkumar patel
So, once it will go, then '27, it will also give a very good fruit in terms of specialty chemicals as well.
Question
Bharat Shah: Yes. Thank you, Naresh Bhai, and all the very best.
Answer, krishanchandra parwani
Krishanchandra Parwani: Yes, hi Naresh Bhai, Abhishek Bhai. Congratulations on very strong set of numbers. 3 questions from my side. Firstly, on the margin front, I believe on account of higher CDMO contribution, EBITDA margins have jumped to almost like 25%. Do you think that with further ramp-up of CDMO business and solar power benefit, your margins could reach 26%, 27%? Or you think 25% is a peak for us? Abhishek Patel : So, on the margin side, as you know that we have improved GM by 281 basis points in this financial and EBITDA of 5%, and we expect quarter-on-quarter improvement going forward in next financial year also.
Answer, krishanchandra parwani
It will be always a sequential improvement in next financial year on the revenue as well as on the margin side. But on a blended side, we can expect that we will cross the EBITDA margin for the full year of the highest peak EBITDA margin of more than 23.5%, which we recorded our highest margin. But obviously, these margins are sustainable and the way the business is going, these are definitely a sustainable margin.
Answer, nareshkumar patel
Nareshkumar Patel: Yes. It is – the validation is under review, and it will be definitely start from FY '26, the commercial supply from second CDMO, from Block 2 of Unit-2.
Answer, nareshkumar patel
Nareshkumar Patel: As everybody knows that it is publicly available, the apixaban is expiring in '26. So, the demand already started for API and API manufacturing. And we already have a ramp-up in this Q3 as a small quantity, Q4, it will be a little bit higher. And by FY '26, we are expecting to go at a very moderate level against the very minimized in last couple of financial years. Rivaroxaban has an expiry in FY '26, '27. So, it will be ramp up by end of this year. But still, we are selling some quantities to our partners in Europe as well as in India.
Answer, krishanchandra parwani
Krishanchandra Parwani: Understood. Understood sir. Thank you so much for patiently answering my question. Wish you all the best, sir. Page 8 of 21 Ami Organics Limited Jan 29, 2025 Nareshkumar Patel: Thank you, sir.
Question
Sudarshan Padmanabhan: Yes, thank you for taking my questions. Sir, quite happy to see the ramp-up in the Pharma Intermediates being much, much faster than expected, thanks to the CDMO. Sir, my question is today, what is the capacity utilization, and whatever the CAPEX that we have done in the past. Given that the existing product itself is doing well for us, and there are multiple products that are there, do we have capacities in place to cater the kind of growth that you talked about to the INR 1,000 crores? Or do you think that we will have to acquire more land? Can you give some colour?
Answer, abhishek patel
Abhishek Patel: From a capacity front, let me update that at Unit-1 Sachin, capacity is more than 70% utilized. At Unit-2, 50% capacity utilization we have achieved in Block 3, which is already capitalized. And at Unit-3, the capacity utilization is 50%. So, we have room available for Pharma Intermediate business at Unit-2, and the next block is already inaugurated block #2 and block #1 is also expected to get commercialized by end of this March quarter. So, it will cater largely our capacity requirement for next 2 to 3 years requirement. And for Spec-Chem business, the capacity is already at 50% utilization at 50% level. So, that will also cater our capacity requirement for next 3-year time.
Answer, abhishek patel
For the new business of Electrolyte Additive, you already know that CAPEX is going on, which is expected to get completed by H1 FY '26, and that will again secure our revenue requirement for next 3 years. So, this way, we are quite very well placed to support our growth for next year. And of course, it's an industry cycle. So, as and when it's required, maybe 1.5, 2 years in advance, citing the new next level of revenue growth, we will have additional land acquired as and when required. Even today also, we have one 8,000 square meter land available at Sachin GIDC, which can be used for some additional requirement. But for high CAPEX, we can have additional land in future.
Question
Sudarshan Padmanabhan: So, both has increased. Sir, just taking forward the previous participants, the margins today is at 25% with around 50% to 60% utilization across both the plants. Intuitively, as the CDMO Page 9 of 21 Ami Organics Limited Jan 29, 2025 proportion increases, from the current products and the new products, I am not talking about next year, say 3 years down the line. Should we be looking at, say, a margin closer to, say, 30%, which is also something a lot of CDMO players are doing, and it's not very different. So, just wanted to understand a bit about how much of operating leverage as you scale up your business environment.
Answer, abhishek patel
Abhishek Patel: So, as you know that CDMO business has just ramped up in this Q3 FY '25. And with commercialization of other 2 block also, our operational efficiency will again kick in. And it will definitely go beyond the 25% mark, no doubt on this. It can reach to, let's say, 27% to 30% also. But you have to understand that this is a CDMO business, not the API, it's an intermediate business. So, that industry, other player, we maintain ourselves a little conservative as against others for guiding EBITDA margins.
Question
Nikhil Mathur: Good morning, all. Many congratulations to Naresh Bhai and team for such great execution. My first question, Naresh Bhai, is on your management commentary that the pipeline of CDMO projects is progressing well. So, just wanted to understand, are you talking here about the current couple of patented products which are kind of scaling up? Or you're also talking about projects which are beyond, let's say, FY '27, '28, which will kind of progress to Phase-II, Phase-III in the next 12 months, and you will get visibility over the next 12, 15 months or so. So, I just wanted to understand if you can split between the next 12, 15 months, and beyond that as well, what is the visibility
Answer, nareshkumar patel
Nareshkumar Patel: Thank you, Nikhil Bhai. Due to confidential nature of the agreements, and because it's clinical trials, I can't disclose more on that, but you are rightly saying that I am talking about the existing as well as the new CDMO, CMO, which will be matured in '27, '28, '29. So, these all are moving very good, and it's a strong robust pipeline we have, with multiple application in terms of pharmaceutical final dosage form. So, several are moving from Phase-II to now Phase-III, some are Phase-III to the approval stage. So, that will be coming in '27, '28 like that.
Question
Nikhil Mathur: So, can we extrapolate, sir, that the current success that you are seeing on the patented side, that is leading to better and more inquiries ever since this success has been visible to other customers as well? Can it be assumed?
Answer, nareshkumar patel
Nareshkumar Patel: You can say like that. But for me, I can say that I started my career in this Company on clinical trial only, and then I move on to the Generic. So, we have a lot of molecules which we supply sometimes in a very early-stage development or some are in the later stage development. But Page 10 of 21 Ami Organics Limited Jan 29, 2025 whoever the customers who are big names in Europe or U.S. or in Japan originators, they now also realize that we are fully capable enough to execute at a very large-scale production for any kind of requirement in terms of regulatory as well as in terms of supply chain, without any deviation or without any hurdle. So, that is one of the things which gives us the confidence. Definitely, you say is one of the right thing that, yes, with the success of this current project gives a lot of confidence to our buyer, and that also encouraging them to give us more project to us as well.
Question
Nikhil Mathur: Got it. Sir, another question I had was a slightly longer-term horizon. The peptide-based development is kind of gaining, it always has been in prominence, but it is only going up and will go up in the coming 10, 15 years as well. We talk about GLP-1, but at a very broad level, peptides are finding or they are getting tested and tried for multiple other indications as well. And hence, an assumption that next 10, 15 years, a company which is on the chemistry side will have to be in the larger molecules and essentially on the peptide side as well. So, any broad thoughts you can share on how Ami Organics is placed to latch on to this tailwind, maybe not in the next 2, 3 years, bu
Answer, nareshkumar patel
Nareshkumar Patel: Ami Organics is chemistry-driven company, and we are very strong in chemistry. This is our core strength. And based on that, we had nurtured our business in a horizontal manner. Peptide is the future, definitely, but it is not solution for all the disease. That is definitely peptide is used for some disease, but it is not future for all the disease. Synthetic chemistry or synthetic drug will never phase out in the system, right? And there is a huge potential available for us.
Answer, nareshkumar patel
In fact, in peptide also, synthetic chemistries are required, and there are also opportunity available for us, and we are already catering this kind of small opportunity what we have, we are getting it. But it's not our core area of bio. People are rushing towards the gold. I don't want to put myself into the same rush, because by this way I am risking my existing infrastructure as well as my future of my company. So, we are a highly focused company, we know our strength and weaknesses, and we are focusing on that area only. So, peptides may be good for someone, but it is not that great for me for today or for the future.
Question
Nikhil Mathur: Understood, sir. And just one final question, if I may please squeeze in. On the base intermediate portfolio, which is on the generic side, can you give some sense, sir, how EBITDA per tonne or if you can talk about margins, how margins have played out in last 12 months or so? And if there is a recovery at some point in time, maybe not this year, but let's say, in FY '27 or sometime, can there be a big reversal in EBITDA per tonne or margins, whichever you want to talk about?
Answer, nareshkumar patel
Nareshkumar Patel: To be very honest, due to the nature and sensitivity of some agreements as well as commitment, we have stopped doing this bifurcation and all because it is impacting on our future contracts as Page 11 of 21 Ami Organics Limited Jan 29, 2025 well. So, yes, we are committing to improve ourselves, and that you can see in last 10 quarters, 12 quarters.
Show 16 more questions
Question
Nikhil Mathur: Sir, I am talking about the portfolio where there is pricing pressure last couple of years, due to demand or Chinese dumping.
Answer, nareshkumar patel
Nareshkumar Patel: As I told you every time that Chinese pressure is not directly impacting us. It is impacting to my manufacturer. You can see my all last 4 quarters where I did the commentary, you can get your answer from that as well, and then we find out the way to how to maintain our margin there as well.
Question
Rohit Nagraj: Thanks for the opportunity, and congrats on a very good set of numbers. So, first question is on the Pharma Intermediates front, excluding the CDMO part. So, this is just the beginning of 2025. So, how are we expecting the pricing environment from our customers, given that the last couple of years have been relatively benign, although it is stable. But given that hopefully, the inventory situation, et cetera, has been managed, whether there is an improvement as far as the 2025 contracts are concerned? So, your views from the customer interactions. Thank you.
Answer, nareshkumar patel
Nareshkumar Patel: Apart from the CDMO patented product agreements, raw material prices is stabilized. Our topline is also now stabilized. In the past, when the problem arise for our end user, we changed our contracts to the spot basis and now we return back to the contract. And this contract is now very well executed and that contract also and rolling forecast also giving us a good visibility for us for the next 1 year, 1.5 years. So, that's why we are very much confident about our margin claim, whatever we are announcing, even our incremental forecast, the revenue forecast for this quarter also based on these contracts as well as the visibility, which is provided by the generic uptake in manufacturers from us only.
Question
Rohit Nagraj: That's helpful. Second question on the Battery Chemicals and Semiconductor. So, here, still, we are at initial stage in terms of commercialization of the plant as well as qualifications. Maybe in FY '27, '28, when we will start the supplies, what is the kind of revenue potential that we are looking at, and whether the margins also will be in a similar range of CDMO or there will be change in terms of the margin profile for these 2 particular products? Thank you.
Answer, nareshkumar patel
Nareshkumar Patel: In terms of the capacity point of view, we already announced that we are putting a plant for 4,000 metric ton inclusive of all additives, which will give you the guidance about the revenue as well as the margin right from beginning. When we develop, we always said that the margin Page 12 of 21 Ami Organics Limited Jan 29, 2025 will be better than Specialty, but lower than Pharma. So, this is the same thing which is right now is applicable for us in terms of Electrolyte Additives as well.
Question
Rohit Nagraj: And the same goes for Semicon as well?
Answer, nareshkumar patel
Nareshkumar Patel: No. Semicon is a very different ball of game, where we are the only company in India, who are right now have a good situation and position ourselves in this basic chemical supply, where the margins are much higher than the Pharma as well as CDMO, which it may vary from 40% to 65%, depends on which product at what scale and this all depends on customer to customer as well. So, it is not a low-margin product at all, because it's a very high purity molecules, which we are making, which is a very unique strength of Baba Fine Chem, which is they know the know-how how to produce this kind of molecule.
Question
Prashant Nair: Yes, good morning, everyone. Naresh Bhai, just one clarification. When you say CDMO, are you referring to all sales that you make to innovator pharma companies? Or is there any other way you're splitting the business?
Answer, nareshkumar patel
Nareshkumar Patel: See, mostly, Ami Organics is doing the CDMO only for the innovator pharma company or the innovator pharma company’s toll manufacturer based in Europe or in India. So, we don't do the generic CDMO or CMO, because we are way beyond of these kind of things. So, it's a small company, very initial company, they can do this kind of big CMO, but we are doing only CDMO, CMO for originators, either directly or supplying to the toll manufacturer of the originators based in Europe, China or in India.
Question
Prashant Nair: Yes. And just a follow-up on this. Would you be able to give a split of the supplies you make to innovators or their toll manufacturers, currently, what proportion would be for products that are off-patent versus, say, those that are under patent or those are still in development? Can you give that split?
Answer, nareshkumar patel
Nareshkumar Patel: Prashant Bhai, if I will be 2 years back, I would love to do this, but this has brought a lot of problem to my marketing team. So, we have now stopped this kind of sharing, because we are generating our own competition. So, we don't want to discuss these kind of things on a call or on one-on-one anywhere.
Question
Prashant Nair: No worries. But would the share of products that are under development or under patent go up over the next few years? I know there's one big contract, which obviously will lead in that Page 13 of 21 Ami Organics Limited Jan 29, 2025 direction. But beyond that, in your pipeline, would you have enough molecules, which are either under development or still on patent that are yet to scale up?
Answer, nareshkumar patel
Nareshkumar Patel: So, I can narrate it like this. You maybe figure out from there. We have more than 570 molecules till last year invoice. Maybe this year, it will be added another 40, 50. Out of that, in a clinical trial, somewhere around 60 to 80 molecules are right now either in Phase-II or Phase-I kind of things, which we are supplying to them. So, from there, you can narrate about whatever you want to get an answer from that.
Question
Yash Gandhi: Hi, sir. Thank you for the opportunity. Just with respect to your CDMO business, could you tell me what is the expected asset turns on the CAPEX that you are estimating by FY '28?
Answer, nareshkumar patel
Nareshkumar Patel: Normally, we target any asset turns which we invest would be 3x. So, similar kind of use. You should make your assumption or calculation like that.
Question
Yash Gandhi: Okay. Okay. And just from a longer-term perspective, because we're seeing some headwinds in the Specialty Chemical business. So, like what was the reason for having that segment? Why don't we just concentrate on the Pharma Intermediate side of the business? I am sorry, I am just new to the company. So, I just wanted to understand the...
Answer, nareshkumar patel
Nareshkumar Patel: No worries. See, let me tell you one thing. If I will be only pharma last 2 years, I will be in a trouble. If I will be in a specialty also, I will be in a trouble. Ami Organics is always focusing on sustainability and long-term growth. And what happened that our policy, right from beginning is that not depend on one customer, not depend on one product, not depend on one area. And this is how we develop Pharma, Agro, Specialty, Polymer, Petrochemicals.
Answer, nareshkumar patel
So, if one segment will not perform well, other segment will help support to us. And that is one of the reasons that every year, every quarter-on-quarter, we have an improvement in our revenue. And also, it has been also giving us an improvement in our operating leverage as well. So, these are multiple things which help us to remain in the position. And not only that Specialty Chemicals is also very lucrative. It required a lot of efforts to make viable for that, and that's what we are doing right now. We’re also new in Specialty, last 4 years only, we enter in this.
Answer, nareshkumar patel
So, we are also learning, and we learn a lot of things in that, and that will give us a foot in the upcoming years as well.
Question
I remember not too long back, there were questions on margins being ever recovering. My question is, I know you have expanded on the Battery Chemicals segment, but perhaps with the geopolitical changes that have happened, has our stance as a company changed or altered for this?
Answer, nareshkumar patel
Nareshkumar Patel: No, because we have an agreement in place, and our position is great in terms of the competition against the competitor base in China as well. Thing is that our buyers, so they have some limitations to start. So, once that limitation is over and they got the green light from the final OEM EV manufacturer, it will be ramped up very quickly for us. If that not happen, then market is open for everyone. And then in that case, we are very happy in that to cater that worldwide as well.
Question
Rikin Shah: All right. Sir, in terms of a very molecule-specific question, there is a lot of activity by Johnson & Johnson and CAPLYTA, and they have done an IMPD filing. So, they estimate this asset to be more than $5 billion, and we sort of have a process patent for the intermediates of lumateperone. So, is there any sort of possibility of having an early entry into this molecule?
Answer, nareshkumar patel
Nareshkumar Patel: We've already done that with our partners. There are 3 partners who had already filed, first to file, and now we are waiting for their upcoming. So, we are already there.
Question
Manav Kapasi: Okay. And ex of BFC, if you could give us the growth for this quarter?
Answer, nareshkumar patel
Nareshkumar Patel: We already announced that this quarter growth, the overall year will be 35%. Page 15 of 21 Ami Organics Limited Jan 29, 2025 Manav Kapasi: No, no, I am asking for the Spec-Chem business. ex of BFC, what would be the growth?
Answer, abhishek patel
Abhishek Patel: Ex of BFC, the growth anticipated for full year is more than 15%.
Question
Jason Soans: Sure, sir. So, one thing is for sure, sir, that your CDMO business will definitely, in that mix, the revenue contribution must have increased quite a bit for that. Yes. So, sir, just in terms of that, you did mention that your tailwinds are strong for CDMO and you target to reach INR 1,000 crores. That's your target aim by FY '28. So, currently, sir, what is the revenue size for CDMO?
Answer, abhishek patel
Abhishek Patel: The CDMO business last year was INR 90 crores. This year, we have already crossed more than double of that last year's business. But as I mentioned, we are not giving the segment-wise revenue splits from this year onwards.
Question
Maitri Shah: So, I just wanted to know, firstly, congratulations for the great results. I just wanted to know the next 2 years kind of guidance and the growth that we are expecting in the topline and the margin?
Answer, abhishek patel
Abhishek Patel: So, we always say that we want to double ourself in 3 years' time. And so that's a 25% to more than 25% growth guidance we are committing.
Question
Prashant Nair: Yes. Thank you. Abhishek, you gave some outlook on margins for next year in your initial comments. Can you please repeat that, I don’t think I was able to get that clearly at the time?
Answer, abhishek patel
Abhishek Patel: So, as on date for 9 months, our blended margin is 21% in 9 months FY '24. Obviously, we are expecting it to improve in Q4 also. And for FY '26 for full year, we are expecting this margin on a blended basis to reach at a peak or highest margin ever reported by Ami Organics. It will be on a blended basis. Sequentially, it will improve from Q1 to Q4 for next financial year.
Question
Prashant Nair: All right. Thank you. That’s all for me.
Answer, abhishek patel
Abhishek Patel: For CAPEX of INR 170 crores, that is for the purpose of Electrolyte Additive business, which is going on. We have already signed some supply contracts, and we have long-term visibility available for Electrolyte Additive business, and we are going ahead with this business. But for Solution business, which is the Korean JV, which we announced earlier, that status quo, we are maintaining, because we don't want to rush into the market, which is yet to get fully developed and we don't want to allocate capital or struck our capital. We are very cautious in this business, and we'll take a call at a relevant level. Page 20 of 21 Ami Organics Limited Jan 29, 2025 Participant: Okay. Thank you, sir. Sir, one small question.
Answer, nareshkumar patel
Nareshkumar Patel: We don't have any ARV. Only Dolutegravir is there, but that is almost contributing 1% of the total revenue. Participant: Okay. Okay, sir. That’s all, sir. Perfect, sir. Thanks a lot, sir .
Questions about this call
- When was the Acutaas Chemicals Q3 FY25 earnings call transcript filed?
- Acutaas Chemicals filed the transcript with the exchange on 1 Feb 2025. This page is built from that transcript.
- What does this page list?
- 50 statements from the transcript across 7 topics, 45 of them with a figure. Each statement is shown with the transcript sentence it came from.
- Are the analysts' questions included?
- Yes. 26 questions and management's answers are listed in the order they were asked, as the transcript prints them.
- Who wrote this page?
- DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.